Background -Previous studies have shown that both salmeterol and formoterol act as partial P2 receptor agonists in terms of antagonising the extrapulmonary responses to fenoterol in normal subjects. The aim ofthe present study was to extend previous observations in evaluating the effect of prior treatment with salmeterol and formoterol on bronchodilator responses to fenoterol, a full P2 receptor agonist, in patients with asthma. Methods -Ten stable asthmatic patients of mean (SE) age 37 (3.7) years and forced expiratory volume in one second (FEV,) 59-5 (4-1)% of predicted completed the study. One hour after inhaling single doses of placebo, salmeterol 25 jg, or formoterol 12 jtg, dose-response curves to repeated doses of inhaled fenoterol were constructed (cumulative doses of 100-3200 pg).
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Measurements of airway and systemic P2
receptor mediated responses were made at baseline, after inhalation of placebo, salmeterol, or formoterol, and after each dose of fenoterol. Results -Salmeterol and formoterol produced significant bronchodilation compared with placebo (mean difference and 95% CI compared with placebo): FEV,, salmeterol 0-41 (95% CI 0-13 to 0.69) 1, formoterol 0-47 (95% CI 0-19 to 0-75) 1. Salmeterol and formoterol had no significant effect on systemic responses compared with placebo. There were no significant differences in peak airway responses to fenoterol after treatment with salmeterol or formoterol compared with placebo (mean (pooled SE)): FEV,, placebo 2.84(0-03)1, salmeterol 2.87 (0.03)1, and formoterol 2-88 (0.03)1. There were no significant differences in the area under the dose-response curve for any of the parameters during the dose-response curve following treatment with salmeterol or formoterol compared with placebo. There was no difference in the slope of the doseresponse curves to fenoterol for FEVy or forced expiratory flow (FEF2575) after treatment with salmeterol or formoterol compared with placebo, although there was a significant (p<005) attenuation of the slope in the dose-response curve for the peak expiratory flow rate (PEFR). . In addition, all subjects were required to have a normal physical examination, 12 lead ECG, haematology and biochemical screen. All subjects gave written informed consent to participate in the study which had been approved by the Tayside committee for medical ethics. At the time of the study all 10 patients were using inhaled corticosteroids in doses of 400-2400,g daily, together with inhaled short acting bronchodilators on an as required basis. In addition, four patients were taking oral theophylline preparations.
Conclusions

PROTOCOL
Patients attended the laboratory between 08.00 and 09.00 hours on three occasions separated by at least one week. Before each visit bronchodilators were withheld for an appropriate period of time (that is, 48 hours for theophylline preparations and eight hours for short acting 32 agonists). A cannula was inserted into a forearm vein to facilitate venous blood sampling. After 30 minutes supine rest, baseline measurements of heart rate, postural finger tremor, serum potassium levels, and spirometric parameters were performed. FEV, was required to be Extrapulmonary responses A standard lead II electrocardiogram was monitored and recorded with a Hewlett-Packard ECG monitor and printer (Palo Alto, California, USA) with paper speed set at 25 mm/s. Heart rate was calculated from the mean of five consecutive R-R intervals.
Finger tremor was recorded by a previously validated method10 using an accelerometer transducer (Entran Ltd, Ealing, UK). Four recordings were made at each measurement and the results were stored on computer for subsequent analysis of total tremor power >2 Hz (mg2/s) using computer assisted autocovariance. The mean of three consistent recordings was subsequently used in the analysis.
Serum potassium levels were measured by flame photometry (IL943 analyser, Instrumentation Laboratory Ltd, Warrington, UK) with analysis being performed in batches at the end of the study, and samples being assayed in duplicate. The coefficients of variation for analytical imprecision within and between assays were 0 41% and 1-04%, respectively. The normal reference range for serum potassium levels in our laboratory is 3 5-5 55 mmol/l.
STATISTICAL ANALYSIS
Data for finger tremor were transformed using logarithm to base 10 to achieve conformation with a normal distribution. Data were then analysed using a Statgraphics software package (STSC Software Publishing Group, Rockville, USA). Baseline values, and values following inhalation of placebo, salmeterol, and formoterol, were compared by multifactorial analysis ofvariance (MANOVA). Where the overall MANOVA was significant, Duncan's multiple range testing was used to establish where differences were significant. Peak values achieved during the dose-response curve by each individual were obtained, regardless of the doses at which they occurred, and were compared by MANOVA and Duncan's multiple range testing. Analysis of the responses at individual doses from the dose-response curve was not performed in order not to confound the error. The area under the curve for each parameter was also obtained using the trapezoidal rule and compared by MANOVA. In order to compare the overall dose-response curves least squares regression analysis was performed on the linear part of the curve for each individual and the resulting gradients were compared by analysis of variance.
A probability of p<0 05 (two tailed) was taken to be of significance for all tests. Values are given in the text as means (pooled SE). Differences from placebo, where significant, were calculated as means and 95% confidence intervals. the peak values achieved or in the overall response curves.
In contrast to the present study, we previously shown in normal subjects thE haled salmeterol 300,ug and formoterol antagonise the extrapulmonary 12 rec mediated responses to both endogenou renaline released during exercise and in] fenoterol.6 This apparent discrepancy m: explained by the difference in doses of long acting 12 agonist used in the two studies. In the present study it is likely that a relatively low degree of receptor occupancy occurred, and this did not therefore antagonise the effects of fenoterol. The dose-response curves for systemic 12 effects may, however, be suggestive of a non-significant trend towards a reduction in heart rate and finger tremor after treatment with salmeterol compared with placebo. Another factor worth considering is that receptor occupancy may be greater at steady state after 10 000 chronic dosing as compared with single dosing.
However, as 12 receptor downregulation and associated subsensitivity to salbutamol occurs after chronic dosing with salmeterol," it would not be possible to separate out this phenomenon from that of 12 receptor antagonism. The primary aim of the present study was to evaluate the effect of ihese long acting 12 agonists on bronchodilator responses to fenoterol. If higher doses of salmeterol or formoterol had been administered it is likely that they themselves would have produced the maximum bronchodilation in an individual, making it 10 000 impossible to assess interactions with fenoterol because of confounding effects on airway geometry. The effect on airway geometry is clearly evident from the shape of the dose-response curves, in that a plateau response for FEV, and PEFR was achieved at a lower dose of fenoterol following active treatment. It should be pointed out that, irrespective of prior treatment, the final airway response achieved was comparable. This is not, however, an explanation for failure to demonstrate antagonism of systemic effects where a ceiling in response did not occur.
In vitro studies are not subject to such coniLE straints. In a study using precontracted guinea 
